Lupin Limited has informed the Exchange regarding a press release dated July 21, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets".
Lupin Limited has informed the Exchange regarding a press release dated July 21, 2023, titled "Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets".